Butabarbital decreases outcomes of sufentanil SL by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep track of Closely. Coadministration of CYP3A4 inducers may well lower sufentanil ranges and efficacy, probably precipitating withdrawal syndrome in people who may have created Actual physical dependence to sufentanil. Discontinuation of concomitantly applied CY... https://jamesx777fqu7.ja-blog.com/profile